GANX NASDAQ
Gain Therapeutics, Inc.
1W: -3.9%
1M: -4.5%
3M: -5.5%
YTD: -46.2%
1Y: -6.0%
3Y: -46.7%
5Y: -77.0%
$1.71
-0.01 (-0.58%)
Weekly Expected Move ±7.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (28)
Gain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration
HC Wainwright Has Positive Estimate for GANX FY2026 Earnings
Gain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate Update
Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Gain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Gain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
Gain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Gain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Q1 EPS Forecast for Gain Therapeutics Boosted by Analyst
Gain Therapeutics GAAP EPS of -$0.61 beats by $0.03
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Gain Therapeutics (NASDAQ:GANX) Trading Up 3.7% – What’s Next?
Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson's Disease
Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Average Rating of “Moderate Buy” from Analysts
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025